Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 80Prostatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 54Esophageal Neoplasms 48Rectal Neoplasms 42Lung Neoplasms 42Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Head and Neck Neoplasms 33Gliosarcoma 31Pancreatic Neoplasms 29Uterine Cervical Neoplasms 28Neoplasms 25Glioma 24Neoplasm Metastasis 23Sarcoma 22Oropharyngeal Neoplasms 21Melanoma 19Esophageal Squamous Cell Carcinoma 19Astrocytoma 18Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Mouth Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Radiation × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡